AEGEAN is a randomised, double-blind ... South America and Asia. Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone AstraZeneca's Imfinzi (durvalumab ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone AstraZeneca's Imfinzi (durvalumab ...

Professor Martin Reck, a member of the AEGEAN Steering Committee, emphasized the importance of this approval for patients in Europe, stating that the combination of durvalumab and neoadjuvant ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been ... s human medicines committee and was supported by results from the phase 3 AEGEAN trial. AZ’s ...

The similarly designed AEGEAN trial in lung cancer ran into ... but the disease still recurs in around half of them. "Adding durvalumab before and after surgery significantly reduced the chance ...

AZ has also reported new data this week from the AEGEAN study of PD-L1 inhibitor Imfinzi (durvalumab) in the phase 3 AEGEAN trial, which looked at the drug as a neoadjuvant regimen with ...

In a separate press release, AstraZeneca announced that the EC has approved expanded use of its blockbuster cancer drug Imfinzi (durvalumab ... from the phase III AEGEAN study, which showed ...

Imfinzi (durvalumab) is a human monoclonal antibody that binds to ... Accessed April 2025. Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, ...

which combines the company’s durvalumab with chemotherapy for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The positive decision follows the company’s AEGEAN ...